This inventor holds 33 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 4 EPO patents, primarily in Biocatalysis Techniques. Top assignees: Codexis, Inc., Merck + Co., Inc., Banyu Pharmaceutical Co. Ltd. Active years: 1997-2025.
Location History:
- Old Bridge, NJ (US) (1997 - 1999)
- Lincroft, NJ (US) (1999 - 2004)
- Rahway, NJ (US) (1998 - 2014)
- Tinton Falls, NY (US) (2014)
- Tinton Falls, NJ (US) (2007 - 2024)
Company Filing History:
17 out of 467 
12 out of 4,770 
2 out of 237 
Years Active: 1997-2025
Areas of Expertise:
Title: The Innovative Contributions of Paul N. Devine
Introduction
Paul N. Devine, based in Tinton Falls, NJ, is a prolific inventor with a remarkable portfolio of 31 patents. His work primarily focuses on advancements in biochemistry and enzymatic processes, leading to significant improvements in pharmaceutical applications.
Latest Patents
Among his latest inventions, the enzymatic synthesis of 4'-ethynyl nucleoside analogs stands out. This innovation eliminates the need for protecting groups on intermediates, thus enhancing the stereoselectivity of glycosylation and reducing production steps for compounds such as EFdA. Furthermore, the invention introduces novel intermediates that are key to this efficient synthesis process. Another notable patent involves engineered penicillin G acylase enzymes, which are crucial for various applications in biochemistry. These engineered enzymes, along with their encoding polynucleotides, represent a significant leap in enzyme development and applications.
Career Highlights
Throughout his career, Paul has contributed to esteemed organizations, including Codexis, Inc. and Merck & Company, Inc. His work in these companies has laid the groundwork for many of his patented inventions, showcasing his ability to blend scientific research with practical applications.
Collaborations
Paul has collaborated with notable colleagues such as Christopher K. Savile and Emily Mundorff, contributing to a collaborative environment that fosters innovation and the development of groundbreaking technologies.
Conclusion
Paul N. Devine’s inventive spirit and dedication to advancing biochemistry continue to impact the industry significantly. His patents reflect a commitment to innovation that not only enhances existing methodologies but also opens up new possibilities in pharmaceutical research and development.